Treating advanced melanoma: Current insights and opportunities

Cancer Management and Research

Volumn 6, Issue , 2014, Pages 349-356

  Tronnier, Michael ^a   Mitteldorf, Christina ^a  

^a Klinikum Hildesheim GmbH   (Germany)

Author keywords

BRAF; CTLA 4; Immunotherapy; Melanoma; Targeted therapy; Treatment

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DASATINIB; ENCORAFENIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MPDL 3280A; NILOTINIB; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PROTEIN KIT; PROTEIN TYROSINE KINASE; SELUMETINIB; SORAFENIB; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIMOGENE ALIPLASMID; VEMURAFENIB;

ADVANCED CANCER; ARTHRALGIA; CANCER IMMUNOTHERAPY; CHILL; COLITIS; DIARRHEA; DRUG FATALITY; EPITHELIUM TUMOR; EYE TOXICITY; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEPATITIS; HUMAN; HYPERTENSION; HYPOPHYSITIS; IMMUNE RESPONSE; KERATOACANTHOMA; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYALGIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THYROIDITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERRUCA VULGARIS;

EID: 84907499926     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S49494     Document Type: Review

References (61)

1. Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol. 2010;28(3):281-286.
2. Tronnier M, Semkova K, Wollina U, Tchernev G. Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach. Wien Med Wochenschr. 2013;163(15-16):354-358.
3. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666-1674.
4. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27(1):3-9.
5. Volkovova K, Bilanicova D, Bartonova A, Letašiová S, Dusinska M. Associations between environmental factors and incidence of cutaneous melanoma. Environ Health. 2012;11:Suppl 1:S12.
6. Garbe C, Peris K, Hauschild A, et al; European Dermatology Forum; European Association of Dermato-Oncology; European Organization of Research and Treatment of Cancer. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline-Update 2012. Eur J Cancer. 2012;48(15):2375-2390.
7. Shtivelman E, Davies MQ, Hwu P, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5(7):1701-1752.
8. Ackerman AB. Malignant melanoma. A unifying concept. Am J Dermatopathol. 1980;2(4):309-313.
9. Mar VJ, Wong SQ, Li J, et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013;19(17):4589-4598.
10. Poulikakos PI, Zhang C, Bollaq G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
11. Lang GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
12. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37(1):61-65.
13. Colomba E, Hélias-Rodzewicz Z, von Deimling A, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94-100.
14. Ihle MA, Fassunke J, König K, et al. Comparison of high resolution melting analysis, pyrosequenzing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E mutations. BMC Cancer. 2014;14:13.
15. Saint-Jean M, Quéreux G, Nguyen JM, et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol. 2014;134(5):1468-1470.
16. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-586.
17. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
18. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
19. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutated advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
20. Göppner D, Müller J, Krüger S, Franke I, Gollnick H, Quist SR. High Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor Vemurafenib. Acta Derm Venereol. Epub February 14, 2014.
21. Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134(5):1351-1358.
22. Argenziano G, Lallas A, Longo C, Moscarella E, Raucci M, Zalaudek I. Dormant melanomas or changing nevi? J Invest Dermatol. 2014;134(5): 1196-1198.
23. Tronnier M, Smolle J, Wolff HH. Ultraviolet irradiation induces acute changes in melanocytic nevi. J Invest Dermatol. 1995;104(4): 475-478.
24. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
25. Menzies AM, Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer. 2013;49(15):3229-3241.
26. Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, does escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metatastic melanoma. J Clin Oncol. 2013;31(Suppl 15;abstract 9028).
27. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251-255.
28. Jarkowski A, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog. 2014;13:1.
29. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
30. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13): 2139-2146.
31. Ascierto PA, Berking C, Agarwala, et al. Efficacy and safety of the oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol. 2012;30(Suppl;abstract 8511).
32. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanomas with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
33. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-4023.
34. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568-574.
35. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009;22(11):1446-1456.
36. Minor DR, Kashani-Sabet M, Garrido M, O’Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18(5):1457-1463.
37. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26): 3182-3190.
38. Blanchard T, Srivastava PK, Duan F. Vaccines against advanced melanoma. Clin Dermatol. 2013;31(2):179-190.
39. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19: 565-594.
40. Hodi FS, O’Day SJ, Mc Dermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-723.
41. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
42. Yuan J, Adamow M, Ginsberg BA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011;108(40):16723-16728.
43. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-2526.
44. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Translat Med. 2012;10:107.
45. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):11293-12297.
46. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
47. Grosso J, Horak CE, Inzunza D, et al; Keck School of Medicine of the University of Southern California, Los Angeles, CA; Dako North America, Inc., Carpinteria, CA. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO4538) J Clin Oncol. 2013;31(Suppl;abstract 3016).
48. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2): 134-144.
49. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
50. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol. 2013;31(Suppl;abstract 9010).
51. Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol. 2014;109(4):320-326.
52. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635-643.
53. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003;22(20):3188-3192.
54. von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer. 1988;61(6):1071-1074.
55. Temple-Oberle CF, Byers BA, Hurdle V, Fyfe A, McKinnon JG. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol. 2014;109(4):327-331.
56. Doukas J, Rolland A. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther. 2012;19(12):811-817.
57. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658-670.
58. Andtbacka RHI, Collichio FA, Amatruda T, et al; Department of Biostatistics and Epidemiology; Amgen, Inc.; Rush University Medical Center. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-Vec) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31(Suppl;abstract LBA9008).
59. Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res. 2014;6:279-289.
60. Slominski AT, Carlson JA. Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc. 2014;89(4):429-433.
61. Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using neoadjuvant approach. Clin Dermatol. 2013;31(3):237-250.